INTERMUNE BEGINS PIRFENIDONE PROGRAM

A A

InterMune has announced that patient enrollment has begun in CAPACITY, the company's Phase III clinical program to evaluate pirfenidone, a small molecule p38-gamma inhibitor, as a treatment for patients with idiopathic pulmonary fibrosis (IPF).

CAPACITY includes two multinational, randomized, double-blind, placebo controlled Phase III trials, named CAPACITY 1 and CAPACITY 2, designed to evaluate the safety and efficacy of pirfenidone in IPF patients with mild to moderate impairment in lung function. The primary endpoint of both trials is lung function, as measured by change in forced vital capacity (FVC). The two trials will enroll a total of approximately 580 patients at over 120 centers in North America and Europe.